Two tiny peptide fragments—one from substance P, one from IGF-1—that synergize to heal corneal wounds the nerves can no longer repair, and why this academic breakthrough never became a pharmaceutical product

In 1996, a research team at Osaka University discovered something unexpected about how the cornea heals. Substance P—a neuropeptide released by corneal sensory nerves—does almost nothing to corneal epithelial cells on its own. IGF-1—a growth factor circulating in tears—does only a little on its own. But put them together, and corneal epithelial cells migrate and adhere with dramatically greater efficiency than either signal alone. The effect was synergistic, not merely additive.

This discovery illuminated a fundamental principle of corneal biology: the nerve-derived signals that maintain the corneal surface are not single molecules acting in isolation. They are combinatorial codes. When corneal nerves are damaged—as in neurotrophic keratopathy—the surface breaks down not because one signal is missing, but because the synergy between multiple signals is disrupted.

The Osaka group took the next logical step: they identified the minimal peptide fragments responsible for each signal (FGLM-NH₂ from substance P, SSSR from IGF-1), formulated them as eye drops, and tested them in patients with persistent corneal defects that had resisted conventional treatment. The results—89% complete healing—were striking. But the story ends there, at least commercially. No pharmaceutical company developed the approach, no randomized trial was conducted, and cenegermin arrived with FDA approval through a different biological pathway. The SP/IGF-1 combination remains one of the most scientifically elegant approaches to corneal healing that never became a drug.

Quick Facts: SP at a Glance

What Is SP/IGF-1 Ocular?

Pronunciation: ess-pee eye-jee-eff-one OCK-yoo-lar

Every time you blink, your corneal nerves release a cocktail of neuropeptides into the tissue. One of them is substance P—an 11-amino-acid molecule better known for its role in pain signaling but quietly essential for corneal surface maintenance. Another signal in the mix is IGF-1, a growth factor present in tears. Individually, neither substance P nor IGF-1 does much for corneal epithelial cells. But together, they trigger a synergistic response that drives epithelial migration and adhesion—the two processes the cornea needs to heal a wound.

SP/IGF-1 Ocular refers to a combination of two synthetic tetrapeptides—FGLM-NH₂ (the minimal active fragment from the C-terminus of substance P) and SSSR (the minimal active sequence from IGF-1)—delivered as eye drops. The tetrapeptide approach was deliberate: the full-length parent molecules are larger, less stable, and potentially immunogenic. The fragments retain the corneal healing activity in a simpler, more practical formulation.

This combination was developed entirely within academia by Teruo Nishida, Naoyuki Yamada, and colleagues at Osaka University. It was never licensed to a pharmaceutical company, never entered industry-sponsored clinical trials, and never received a brand name. It exists as a proof of concept—a demonstration that the nerve-derived synergistic signals driving corneal maintenance can be replaced therapeutically when the nerves themselves are damaged.

Origins and Discovery

The SP/IGF-1 story begins with a question about why corneal nerves matter for corneal healing—a question that seems obvious in retrospect but wasn't at all obvious in the 1990s.

Clinicians had long observed that when corneal nerves are damaged—by herpes infection, diabetes, surgical transection, or trigeminal nerve injury—the corneal surface deteriorates. Persistent epithelial defects develop, resist treatment, and can progress to stromal melting and perforation. The condition was called neurotrophic keratopathy, and the assumption was that the nerves provided some kind of "trophic" support to the epithelium. But nobody had identified what, specifically, the nerves were providing.

Yamada et al. (1996, PMID 8841432) provided the answer—or at least a major part of it. Working with cultured corneal epithelial cells, they showed that substance P (the primary neuropeptide in corneal sensory nerves) had no direct effect on epithelial cell migration. IGF-1 (present in tears and aqueous humor) had only a modest effect. But the combination of substance P and IGF-1 produced synergistic migration—cells moved dramatically faster and farther than with either factor alone.

The follow-up work was equally elegant. Yamada et al. (1997, PMID 9088746) confirmed the synergy in living rabbit corneas. Yamada et al. (2003, PMID 12939296) showed that SP/IGF-1 combination restored epithelial barrier function in a rat model of neurotrophic keratopathy. And critically, the group identified the minimal active fragments: FGLM-NH₂ from substance P and SSSR from IGF-1—four amino acids each, small enough to be stable as eye drops.

By 2008, the tetrapeptide combination had been tested in patients. The 89% healing rate in persistent epithelial defects was the culmination of twelve years of systematic work—from in vitro discovery to animal validation to human proof of concept.

Mechanism of Action

The SP/IGF-1 mechanism is a textbook example of biological synergy—two signals that accomplish almost nothing independently but produce a robust therapeutic effect in combination.

NK-1 Receptor Priming (FGLM-NH₂)

FGLM-NH₂, the C-terminal tetrapeptide of substance P, activates the neurokinin-1 (NK-1) receptor on corneal epithelial cells. NK-1 activation does not directly cause cell migration. Instead, it "primes" the cell—upregulating intracellular signaling cascades that make the cell responsive to subsequent migration and adhesion cues. Think of it as unlocking the car but not starting the engine. The cell becomes ready to move but requires a second signal to actually go.

IGF-1R Adhesion Signal (SSSR)

SSSR, the minimal active sequence from IGF-1, activates the IGF-1 receptor on the same epithelial cells. IGF-1R signaling promotes cell adhesion to extracellular matrix components—fibronectin, collagen IV, laminin—the structural proteins that form the basement membrane underlying the corneal epithelium. When an epithelial cell migrates across a wound, it needs to adhere to the exposed stroma to form a stable surface. SSSR provides this adhesion signal.

The Synergy

The synergistic effect emerges because migration and adhesion are sequential, coupled processes. A cell that is primed to move (NK-1 activation) but cannot adhere to the substrate will slide off or die. A cell that can adhere (IGF-1R activation) but is not primed to migrate will stay put. The combination—prime, then adhere—produces coordinated directional migration across the wound bed, closing the epithelial defect.

In neurotrophic keratopathy, this synergy is precisely what is missing. Damaged corneal nerves no longer release substance P, so the NK-1 priming signal is absent. Without priming, IGF-1 in the tears cannot drive effective migration. The epithelial defect persists because the combinatorial code is incomplete. Exogenous FGLM-NH₂ + SSSR eye drops restore the code.

Comparison with Other Approaches

Cenegermin (NGF) restores corneal healing by regrowing the nerves themselves—addressing the upstream cause. RGN-259 (thymosin β4) promotes cell migration through cytoskeletal remodeling—a nerve-independent mechanism. SP/IGF-1 replaces the downstream signal that damaged nerves can no longer provide—a middle path between nerve restoration and nerve-independent healing.

Key Research Areas and Studies

The Foundational Synergy Discovery

Yamada et al. (1996, PMID 8841432) established the core finding: substance P and IGF-1 synergize to promote corneal epithelial cell migration in vitro. This was not a marginal effect—migration rates with the combination dramatically exceeded the sum of individual effects. The study also demonstrated that the C-terminal tetrapeptide of substance P (FGLM-NH₂) retained the synergistic activity, enabling the tetrapeptide formulation strategy.

Animal Model Validation

Yamada et al. (2003, PMID 12939296) tested SP + IGF-1 in a rat model of neurotrophic keratopathy created by trigeminal nerve transection. The combination restored epithelial barrier function and accelerated wound closure. This confirmed that the in vitro synergy translated to the in vivo setting and that the mechanism was relevant to the specific pathology of NK.

Human Clinical Data

Yamada et al. (2008, PMID 18511539) conducted an open-label clinical study of FGLM-NH₂ + SSSR eye drops in patients with persistent corneal epithelial defects due to neurotrophic keratopathy. Nine eyes received the tetrapeptide combination (1 mM each, 4–6 times daily). Results: 8 of 9 eyes (89%) achieved complete epithelial resurfacing. Five of nine (56%) healed within two weeks. These were refractory defects—patients who had failed other treatments.

Chikama et al. (2008, PMID 18158595) published additional case series data confirming the clinical applicability of the SP-derived peptide approach for persistent NK defects.

Mechanism Review

Nishida et al. (2007, PMID 17131028) published a comprehensive review of neurotrophic mediators in corneal wound healing, contextualizing the SP/IGF-1 synergy within the broader signaling network that maintains the corneal surface. This review remains one of the best summaries of why corneal nerves matter for epithelial health.

Claims vs. Evidence

The Human Evidence Landscape

The entire human evidence base for SP/IGF-1 ocular therapy comes from one research group at Osaka University and consists of open-label studies with no randomized controls.

Yamada et al. (2008) — Primary Clinical Study

Design: Open-label clinical study. N: 9 eyes with persistent epithelial defects due to neurotrophic keratopathy. Intervention: FGLM-NH₂ (1 mM) + SSSR (1 mM) in saline, applied 4–6 times daily until defect closure. Primary findings: Complete epithelial resurfacing in 8/9 eyes (89%). Healing within 2 weeks in 5/9 eyes (56%). Limitations: No control group. No randomization. No masking. N=9. Single center. Refractory cases (prior treatment failure)—this may overestimate or underestimate effect size depending on selection. PMID: 18511539.

Chikama et al. (2008) — Confirmatory Case Series

Design: Case series. N: Multiple patients (exact N varies by report). Intervention: SP-derived peptide + IGF-1 eye drops. Primary findings: Successful healing of persistent NK defects confirmed in additional patients. Limitations: Case series—no control, no standardized protocol, no statistical analysis. PMID: 18158595.

What's Missing

No randomized controlled trial has ever been conducted. No independent replication outside the Osaka group. No dose-finding study. No long-term follow-up. No data on recurrence rates after initial healing. No safety database beyond the reported studies. No pharmacokinetic data. No data in non-NK corneal conditions (dry eye, post-surgical, traumatic). No industry-sponsored study of any kind. The human evidence, while encouraging, represents the absolute minimum needed to establish clinical proof of concept.

Safety, Risks, and Limitations

Known Safety Profile

No adverse events were reported in any published SP/IGF-1 ocular study. The tetrapeptides appear well-tolerated as topical eye drops. No systemic effects are expected—both fragments are small (4 amino acids each), are applied topically to the ocular surface, and have minimal systemic absorption.

Limitations

Minimal safety database. Approximately 9–15 patients total in published studies. This is insufficient to characterize any adverse event that occurs at a rate below ~10%.

No long-term safety data. Treatment duration in published studies corresponds to the time needed for wound closure. No chronic dosing data exists.

NK-1 receptor considerations. Substance P and its fragments activate NK-1 receptors, which are involved in pain signaling, neurogenic inflammation, and other processes. At the low topical concentrations used in eye drops, systemic NK-1 activation is unlikely. But the theoretical concern exists, particularly if higher concentrations or more frequent dosing were considered.

No standardized formulation. SP/IGF-1 eye drops were prepared as academic research preparations. No cGMP-manufactured clinical formulation exists. Stability, sterility, and batch-to-batch consistency have not been validated to pharmaceutical standards.

Availability risk. Because no commercial formulation exists, patients cannot access SP/IGF-1 eye drops outside the original academic setting. This is a practical limitation, not a safety concern, but it means the treatment described in published studies is effectively unavailable.

Legal and Regulatory Status

SP/IGF-1 combination eye drops have no regulatory status anywhere in the world. No IND (investigational new drug) application has been filed with the FDA. No marketing authorization has been sought from any regulatory agency. The clinical studies were conducted under Japanese academic research protocols, not under a formal regulatory development pathway. The tetrapeptides FGLM-NH₂ and SSSR are not individually regulated as drugs. WADA does not prohibit either component. There is no intellectual property barrier to development—the foundational patents have likely expired—but there is also no commercial entity pursuing this approach.

Research Protocols and Formulation Considerations

The clinical formulation was FGLM-NH₂ (1 mM) + SSSR (1 mM) dissolved in preservative-free saline, prepared as sterile ophthalmic drops. Both tetrapeptides are small, hydrophilic, and readily soluble. The simplicity of the formulation—two small peptides in saline—is one of its theoretical advantages over larger protein therapeutics like cenegermin, which require cold-chain storage and complex manufacturing.

Dosing in clinical studies was 4–6 drops daily until the epithelial defect healed. Treatment duration was dictated by clinical response rather than a fixed protocol. The 1 mM concentration was established in preclinical studies as the minimum effective concentration for synergistic activity.

No manufacturing, scale-up, or stability studies have been published. The formulation exists only as an academic preparation—any future commercial development would need to establish cGMP manufacturing, stability testing, and a defined shelf life.

Dosing in Published Research

Note: These are academic research protocols, not standardized clinical dosing. No dose-response relationship has been established. No comparison between different concentrations has been published.

Combination Stacks

Research into SP combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining SP with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Compound	Type	Evidence Tier	Verdict	Primary Mechanism	Target Tissue	Primary Indication	Human Data	FDA Status	WADA Status	Key Limitation
Cenegermin	Recombinant human NGF (118 aa homodimer, 0.002% eye drops)	Tier 1 — Approved Drug	Strong Foundation	TrkA/p75NTR → corneal epithelial survival + nerve regeneration	Cornea	Neurotrophic keratitis	Phase III RCTs (N=48 US + N=156 EU); 69.6% vs 29.2% healing	Approved August 2018 (Oxervate)	Not prohibited	6 drops/day × 8 weeks; frozen storage; high cost; NK indication only
Anti-VEGF Peptides	Aptamer (pegaptanib) + antibody fragments (ranibizumab/brolucizumab) + fusion protein (aflibercept)	Tier 1 — Approved Drug	Strong Foundation	VEGF-A neutralization → anti-angiogenesis + anti-permeability	Retina	nAMD; DME; RVO	VISION (N=1,186); MARINA (N=716); VIEW (N=2,419)	Multiple agents approved (2004–2019+)	Not prohibited	Repeated intravitreal injections; endophthalmitis risk; treatment burden
RGN-259	Thymosin β4 (43 aa) 0.1% ophthalmic solution	Tier 2 — Clinical Trials	Reasonable Bet	Actin sequestration → epithelial migration + anti-inflammatory	Cornea	Neurotrophic keratopathy; dry eye	Phase III NK (N=18; 60% vs 12.5%); Phase II dry eye (N=120)	Not approved (Phase III complete)	Not prohibited	Small Phase III N; competing with approved cenegermin; regulatory path pending
NGF (Ocular)	Recombinant human NGF (same as cenegermin, broader indications)	Tier 3 — Limited Human Data	Reasonable Bet	TrkA → neuroprotection (RGC) + tear film + epithelial trophism	Cornea; retina	Dry eye; glaucoma neuroprotection; AMD	Phase IIa dry eye (N=40); Phase 1b glaucoma (N=60)	Approved for NK only (Oxervate); not approved for dry eye/glaucoma	Not prohibited	No Phase III for non-NK indications; glaucoma Phase 1b showed trends only
SP/IGF-1 Ocular	Tetrapeptide combination (FGLM-NH₂ + SSSR eye drops)	Tier 3 — Limited Human Data	Reasonable Bet	SP/NK-1R priming + IGF-1R adhesion → synergistic epithelial migration	Cornea	Neurotrophic keratopathy (persistent epithelial defects)	Open-label (N=9; 89% healing)	Not approved; no commercial development	Not prohibited	Single research group (Japan); open-label only; no commercial developer
Octreotide (Intravitreal)	Cyclic octapeptide SSA (systemic or experimental intravitreal)	Tier 3 — Limited Human Data	Eyes Open	SSTR2/5 → anti-angiogenic + neuroprotective in retina	Retina	Diabetic retinopathy (proliferative)	Small randomized study (N=46; reduced vitreous hemorrhage)	Not approved for retinal use	Not prohibited	Eclipsed by anti-VEGF therapy; no active development program
PL-8177 (Ocular)	Selective MC1R agonist (theoretical ocular formulation)	Tier 4 — Preclinical Only	Eyes Open	MC1R → NF-κB suppression → ocular anti-inflammatory	Uvea; conjunctiva	Uveitis; dry eye inflammation (theoretical)	None for ocular use	Not approved; no ocular development	Not prohibited	Entirely theoretical; no ocular formulation or clinical data; IBD is active program

Frequently Asked Questions

Summary of Key Findings

1. SP/IGF-1 synergy is a genuine biological discovery. The finding that substance P and IGF-1 synergize to promote corneal epithelial migration—while neither works effectively alone—is well-replicated in vitro and confirmed in animal models. This is real science with mechanistic clarity.

2. Clinical results are encouraging but preliminary. An 89% healing rate in persistent epithelial defects (N=9) is clinically impressive, but the study was open-label with no control group, conducted by a single research team, and has never been independently replicated.

3. The tetrapeptide approach is elegant. Using minimal active fragments (FGLM-NH₂ and SSSR) rather than full-length proteins simplifies formulation, reduces immunogenicity risk, and retains biological activity. This is a design principle worth noting even if the specific therapy remains undeveloped.

4. No commercial development has occurred. Despite encouraging data, no pharmaceutical company has taken SP/IGF-1 eye drops through formal clinical development. The approach has been overtaken by cenegermin, which reached FDA approval through a different mechanism.

5. The evidence gap is structural, not scientific. The missing evidence—randomized controlled trial, dose-finding, long-term follow-up—reflects a lack of commercial investment, not a failure of the biology. The science is sound; the development pathway simply wasn't pursued.

Verdict Recapitulation

The synergy biology is well-established and the clinical proof of concept is encouraging—89% healing in refractory corneal defects is a result that demands attention. Reasonable Bet because the mechanism is sound, the early human data is positive, and the tetrapeptide design is elegant. But the evidence base is thin (N=9, open-label, single center), no independent replication exists, and the absence of commercial development means this approach may never reach the patients who could benefit from it.

For readers considering SP, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source SP

Further Reading and Resources

If you want to go deeper on SP, the evidence landscape for vision & ocular peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Vision & Ocular Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: SP — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Yamada, N. et al. (2008). "Open clinical study of eye drops containing tetrapeptides derived from substance P and IGF-1 for treatment of persistent corneal epithelial defects associated with neurotrophic keratopathy." British Journal of Ophthalmology, 92, 896–900. PMID 18511539
2. Chikama, T. et al. (2008). "Treatment of neurotrophic keratopathy with substance P-derived peptide (FGLM) and insulin-like growth factor 1 eye drops." Cornea, 27 Suppl 1, S62–S67. PMID 18158595
3. Yamada, N. et al. (1996). "Synergistic effects of substance P and insulin-like growth factor-1 on epithelial migration of the cornea." Journal of Cellular Physiology, 169(2), 189–196. PMID 8841432
4. Yamada, N. et al. (2003). "Substance P and IGF-1 restore corneal epithelial barrier function in neurotrophic keratopathy." IOVS, 44(3), 1252–1258. PMID 12939296
5. Nishida, T. et al. (2007). "Neurotrophic mediators and corneal wound healing." Ocular Surface, 5(3), 168–202. PMID 17131028

---